Izrael - hebrejčina - Ministry of Health

pfizer pharmaceuticals israel ltd - somatropin - אבקה להכנת תמיסה לזריקה - somatropin 5.3 mg - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth weight and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

Izrael - hebrejčina - Ministry of Health

pfizer pharmaceuticals israel ltd - somatropin - אבקה להכנת תמיסה לזריקה - somatropin 12 mg - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (height sds<2.5 and parenteral adjusted height sds < -1) in short children born sga (sga - small for gestational age i.e. born small in relation to the length of the fetus development) with a birth witght and/or length < 2 sd who failed to show catch up growth (hv sds < 0 during the last year) by 4 years of age or later. prader willi syndrome for improvement of growth and body composition. adults: for adults who have suffered from growth-hormone deficiency since childhood. for adults who have aquired growth hormone deficiency due to a pituitary pathology causing hypopituitarism.

Izrael - hebrejčina - Ministry of Health

medison pharma ltd - somatropin 5 mg / 1 ml - solution for injection - somatropin - 1. long-term treatment of children with growth failure due to inadequateendogenous growth hormone secretion.2. long-term treatment of growth failure associated with turner syndrome. 3. treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation. 4. replacement of endogenous growth hormone in adults with growth hormone deficiency or either childhood or adult-onset etiology. growth hormone deficiency of either childhood or adult-onset etiology. growth hormone deficiency should be confirmed appropriately prior to treatment.

Izrael - hebrejčina - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 100 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Izrael - hebrejčina - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 50 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less. management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrai

Izrael - hebrejčina - Ministry of Health

abbvie biopharmaceuticals ltd, israel - botulinum toxin type a - אבקה להכנת תמיסה לזריקה - botulinum toxin type a 200 u/vial - botulinum toxin - botulinum toxin - botox is indicated for the symptomatic relief of blepharospasm or vii nerve disorders in patients over 12 years hemifacial spasm and associated focal dystonias as well as the correction of strabismus in patients 12 years of age and above. botox is also indicated for the reduction of the signs and symptoms of spasmodic torticollis ( cervical dystonia) in adults. botox is also indicated for the treatment of dynamic equinus foot deformity due to spasticity in paediatric cerebral palsy patients two years of age or older. focal upper limb spasticity associated with stroke. botox is indicated also for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients aged 65 years or less.management of primary axillary hyperhidrosis in patients who failed other medical symptomatic treatment.symptom relief in adults fulfilling criteria for chronic migraine (headaches on ?15 days per month of which at least 8 days with migrain

Izrael - hebrejčina - Ministry of Health

novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 10 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.

Izrael - hebrejčina - Ministry of Health

novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 10 mg / 1.5 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.

Izrael - hebrejčina - Ministry of Health

novo nordisk ltd., israel - somatropin - תמיסה להזרקה - somatropin 3.3 mg / 1 ml - somatropin - somatropin - children: short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. short stature in children with renal insufficiency. growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with chilhood onset of g.h. deficiency.

Izrael - hebrejčina - Ministry of Health

cartiheal (2009) ltd. - רופא - agili-c implant is a bi-phasic, porous resorbable tissue regeneration scaffold for the treatment of focal articular cartilage and/or osteochondral defects. it is indicated for cartilage and/or bone repair. the implant serves as a scaffold for cellular and matrix ingrowth. the agili-c implant is expected to biodegrade within 6 – 12 months.